Purposely engineered drug-target mismatches for entropy-based drug optimization

Area of Science:

• Biochemistry
• Structural Biology
• Drug Discovery

Background:

• Proteins are dynamic molecules that change conformation upon ligand binding, reducing their possible structures.
• Traditional structure-based drug design often overlooks protein dynamics, limiting its effectiveness.
• A less common binding scenario involves proteins increasing entropy upon ligand binding, enhancing local conformational exploration.

Purpose of the Study:

• To highlight the importance of protein dynamics in drug design.
• To introduce and advocate for entropy optimization as a novel drug design strategy.
• To emphasize the significance of rarely visited binding modes in therapeutic development.

Main Methods:

• Reviewing existing literature on protein dynamics and ligand binding.
• Analyzing the implications of entropy-increasing binding modes for drug discovery.
• Proposing a shift from conventional optimization to entropy optimization in drug design.

Main Results:

• Protein dynamics are essential for understanding ligand binding and its effects.
• Entropy optimization offers a new paradigm for designing drugs targeting specific protein conformational states.
• Drugs can be designed to leverage mismatches with targets by exploiting enhanced conformational exploration.

Conclusions:

• Incorporating protein dynamics, particularly entropy changes, is critical for effective drug design.
• Entropy optimization, by exploiting dynamic information, represents a promising approach for developing innovative therapeutics.
• Understanding and utilizing rarely observed binding modes can lead to more effective drug candidates.